1. Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH 
Ronald B. Goldberg, MD, Vera A. Bittner, MD, MSPH, Richard L. Dunbar, MD, MS, Jerome L. Fleg, MD, George Grunberger, MD, John R. Guyton, MD, Lawrence A. Leiter, MDCM, Ruth McBride, ScB, Jennifer G. Robinson, MD, MPH, Debra L. Simmons, MD, MS, Carol Wysham, MD, Ping Xu, MS, William E. Boden, MD 
The American Journal of Medicine 
Volume 129, Issue 7, Pages 753.e e22 (July 2016)
DOI: /j.amjmed
Copyright © 2016 Elsevier Inc. Terms and Conditions

2. Figure 1
Comparison of baseline and annual follow-up fasting glucose (A), insulin (B), HOMA-IR (C), and HOMA-β (D) values between ERN Therapy and Placebo Treatment groups by fasting glucose status or diabetes (for fasting glucose only). Mean and standard error are depicted. ERN = extended-release niacin; HOMA = homeostatic model assessment; IR = insulin resistance.
The American Journal of Medicine  , 753.e e22DOI: ( /j.amjmed )
Copyright © 2016 Elsevier Inc. Terms and Conditions

3. Figure 2
Percent change in plasma glucose from baseline to year 1, year 2, and year 3 by glycemic status at baseline and randomization treatment assignment. P-values from longitudinal models comparing treatment groups within glycemic status groups. ERN = extended-release niacin.
The American Journal of Medicine  , 753.e e22DOI: ( /j.amjmed )
Copyright © 2016 Elsevier Inc. Terms and Conditions